NASDAQ:IRIX - IRIDEX Stock Price, News & Analysis

$2.00
-0.27 (-11.89 %)
(As of 09/16/2019 04:00 PM ET)
Today's Range
$1.84
Now: $2.00
$2.27
50-Day Range
$2.29
MA: $2.83
$3.60
52-Week Range
$2.22
Now: $2.00
$7.22
Volume156,737 shs
Average Volume37,453 shs
Market Capitalization$27.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.60 million
Book Value$2.20 per share

Profitability

Net Income$-12,810,000.00

Miscellaneous

EmployeesN/A
Market Cap$27.52 million
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.


IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings data on Tuesday, August, 6th. The medical equipment provider reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.04. The medical equipment provider earned $10.43 million during the quarter, compared to analyst estimates of $10.94 million. IRIDEX had a negative return on equity of 39.42% and a negative net margin of 26.02%. View IRIDEX's Earnings History.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for IRIDEX.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $41-44 million, compared to the consensus revenue estimate of $45.02 million.

What price target have analysts set for IRIX?

2 brokers have issued 12-month target prices for IRIDEX's shares. Their predictions range from $7.00 to $10.00. On average, they anticipate IRIDEX's stock price to reach $8.50 in the next year. This suggests a possible upside of 325.0% from the stock's current price. View Analyst Price Targets for IRIDEX.

What is the consensus analysts' recommendation for IRIDEX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.

Has IRIDEX been receiving favorable news coverage?

News stories about IRIX stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IRIDEX earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for IRIDEX.

Who are some of IRIDEX's key competitors?

What other stocks do shareholders of IRIDEX own?

Who are IRIDEX's key executives?

IRIDEX's management team includes the folowing people:
  • Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
  • Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
  • Mr. Romeo R. Dizon, VP of Fin.
  • Ms. Leigh Salvo, Head of Investor Relations
  • Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (9.60%), Vanguard Group Inc. (5.45%), Renaissance Technologies LLC (2.80%), Balter Liquid Alternatives LLC (1.45%), Isthmus Partners LLC (1.09%) and Eidelman Virant Capital (0.95%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon and William M Moore. View Institutional Ownership Trends for IRIDEX.

Which major investors are selling IRIDEX stock?

IRIX stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Eidelman Virant Capital and Alambic Investment Management L.P.. View Insider Buying and Selling for IRIDEX.

Which major investors are buying IRIDEX stock?

IRIX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Balter Liquid Alternatives LLC, Isthmus Partners LLC, River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, LPL Financial LLC and Renaissance Technologies LLC. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove and William M Moore. View Insider Buying and Selling for IRIDEX.

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.00.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $27.52 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.

What is IRIDEX's official website?

The official website for IRIDEX is http://www.iridex.com/.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]


MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel